• No results found

University of Groningen Iron Deficiency and Erythropoietin Excess: Two Sides of the Same Coin? Eisenga, Michele Freerk

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Iron Deficiency and Erythropoietin Excess: Two Sides of the Same Coin? Eisenga, Michele Freerk"

Copied!
9
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Iron Deficiency and Erythropoietin Excess: Two Sides of the Same Coin?

Eisenga, Michele Freerk

DOI:

10.33612/diss.98865528

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Eisenga, M. F. (2019). Iron Deficiency and Erythropoietin Excess: Two Sides of the Same Coin? studies in patients with chronic kidney disease and in the general population. Rijksuniversiteit Groningen.

https://doi.org/10.33612/diss.98865528

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Iron Deficiency and Erythropoietin Excess:

Two Sides of the Same Coin?

Studies in Patients with Chronic Kidney Disease and in the General Population

(3)

Michele Freerk Eisenga

Iron Defi ciency and Erythropoietin Excess: Two Sides of the Same Coin?

Financial support by the University of Groningen, University Medical Center Groningen and Graduate School of Medical Sciences for publication of this thesis is gratefully ac-knowledged.

Further, fi nancial support for the printing of this thesis was also kindly provided by:

2

Michele Freerk Eisenga

Iron Deficiency and Erythropoietin Excess: Two Sides of the Same Coin?

Financial support by the University of Groningen, University Medical Center Groningen and Graduate School of Medical Sciences for publication of this thesis is gratefully acknowledged.

Further, financial support for the printing of this thesis was also kindly provided by:

Copyright © 2019. Michele F. Eisenga

All rights are reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the written permission from the author.

ISBN (printed): 978-94-6361-329-3 Cover design: Erwin Timmerman

Lay-out and printing: Optima Grafische Communicatie, Rotterdam, the Netherlands

Copyright © 2019. Michele F. Eisenga

All rights are reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without the written permission from the author.

ISBN (printed): 978-94-6361-329-3 Cover design: Erwin Timmerman

(4)

Iron Deficiency and Erythropoietin Excess:

Two Sides of the Same Coin?

Studies in Patients with Chronic Kidney Disease and in the General Population

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 30 oktober 2019 om 16.15 uur

door

Michele Freerk Eisenga

geboren op 8 juni 1988

(5)

Promotores

Prof. dr. S.J.L. Bakker Prof. dr. C.A.J.M. Gaillard

Beoordelingscommissie

Prof. dr. I.C. Macdougall Prof. dr. D.W. Swinkels Prof. dr. A.A. Voors

Paranimfen

I. Minović, PharmD, PhD M.R. Postma, M.D.

(6)

TaBlE oF ConTEnTS

Chapter 1 Introduction 9

Iron

Chapter 2 Iron Deficiency, Anemia, and Mortality in Renal Transplant Recipients

Transplant International 2016; 29: 1176-1183

29

Chapter 3 C-Terminal Fibroblast Growth Factor 23, Iron Deficiency, and

Mortality in Renal Transplant Recipients

Journal of the American Society of Nephrology 2017;28:3639-3646

45

Chapter 4 Associations of Different Iron Deficiency Cutoffs with Adverse

Outcomes in Chronic Kidney Disease BMC Nephrology 2018; 19: 225

63

Chapter 5 Association of Hepcidin-25 with Survival after Kidney

Transplantation

European Journal of Clinical Investigation 2016; 46: 994-1001

89

Erythropoietin

Chapter 6 Effects of Erythropoietin on Fibroblast Growth Factor 23 in Mice and

Humans

Nephrology Dialysis Transplantation 2018: Epub ahead of print

105

Chapter 7 Erythropoietin, Fibroblast Growth Factor 23, and Mortality in Kidney

Transplant Recipients Submitted

139

Chapter 8 Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients

with Chronic Heart Failure and Chronic Kidney Disease Journal of the American Heart Association 2019; 8(16):e011130

157

Iron and Erythropoietin beyond CKD

Chapter 9 Iron Deficiency, Elevated Erythropoietin, Fibroblast Growth Factor 23

and Mortality in the General Population of the Netherlands: a Cohort Study

PLOS Medicine 2019;16(6):e1002818

173

Chapter 10 Active Smoking and Hematocrit and Fasting Circulating

Erythropoietin Concentrations in the General Population Mayo Clinic Proceedings 2018; 93: 337-343

(7)

Chapter 11 Rationale and Design of TransplantLines: a Prospective Cohort Study

and Biobank of Solid Organ Transplant Recipients BMJ Open 2018; 8: e024502

207

Chapter 12 Summary, discussion, and future perspectives

Dutch summary / Nederlandse samenvatting Appendix (NtvG article)

Acknowledgements / Dankwoord Author Affiliations

About the author List of publications 235 249 259 273 283 291 295

(8)
(9)

Referenties

GERELATEERDE DOCUMENTEN

As sensitivity analyses, we performed adjustments of the association of ID with mortality as in table 2, model 2, for serum calcium, serum PTH, use of ACE-inhibitors and

additional file 3: Supplemental Table 3, 4, and 5, showing the association of different cutoff values of ferritin and TSAT, adjusted for age and sex, in CKD patients with eGFR<60

Since hepcidin antagonists are currently introduced as potential treatment for iron-restricted anemia, 13 we deemed it clinically relevant to assess whether increased

In our mice with high endogenous EPO levels, and in our mice injected with rhEPO, we assessed bone and marrow mRNA expression of enzymes involved in FGF23 cleavage, including

demonstrated an independent association between higher circulating endogenous erythropoietin (EPO) levels and risk of cardiovascular and all-cause mortality among

In chronic heart failure (CHF) and chronic kidney disease (CKD) patients, correction of anemia with erythropoietin stimulating agents (ESA), targeting normal hemoglobin

The associations we observed between functional iron deficiency, high EPO levels, and mortality led us to explore FGF23 as a potential downstream factor mediating these associations,

The major strength of the current study is the large patient population and that as one of the first large studies smoking behavior was measured in sensitivity analyses by